{"id":"NCT02073656","sponsor":"Gilead Sciences","briefTitle":"Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection","officialTitle":"A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Co-infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-02","primaryCompletion":"2014-11","completion":"2015-12","firstPosted":"2014-02-27","resultsPosted":"2016-10-21","lastUpdate":"2018-11-16"},"enrollment":335,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Virus","HIV"],"interventions":[{"type":"DRUG","name":"LDV/SOF","otherNames":["HarvoniÂ®","GS-5885/GS-7977"]},{"type":"DRUG","name":"RBV","otherNames":[]}],"arms":[{"label":"LDV/SOF 12 Weeks","type":"EXPERIMENTAL"},{"label":"Retreatment Substudy","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) administered for 12 weeks in hepatitis C virus (HCV) treatment-naive and treatment-experienced (including treatment intolerant) participants with chronic genotype 1 or 4 HCV infection who are co-infected with HIV-1.\n\nParticipants who experience confirmed post-treatment virologic failure (relapse) at or before Posttreatment Week 24 may be eligible to be enrolled in the Retreatment Substudy to receive LDV/SOF plus ribavirin (RBV) for 24 weeks.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)","timeFrame":"Posttreatment Week 12","effectByArm":[{"arm":"LDV/SOF 12 Weeks","deltaMin":96.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":41,"countries":["United States","Canada","New Zealand","Puerto Rico"]},"refs":{"pmids":["26196665","27225242","26743093"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":335},"commonTop":["Headache","Fatigue","Diarrhoea","Nausea","Arthralgia"]}}